Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Succinylcholine for Neuromuscular Blockade Reversal in ECT
NCT03532178Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Jan 2019
- Primary completion
- Mar 2022
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by University of California, San Francisco. Started Jan 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03532178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532178.